Ashraf Coovadia to HIV Protease Inhibitors
                            
                            
                                This is a "connection" page, showing publications Ashraf Coovadia has written about HIV Protease Inhibitors.
                            
                            
                            
                                
                                    
                                            
    
        
        
        
            Connection Strength
            
                
            
            1,276
         
        
        
     
 
    
        
        - 
            Biomarkers of Aging in HIV-Infected Children on Suppressive Antiretroviral Therapy. J Acquir Immune Defic Syndr. 2018 08 15; 78(5):549-556.
            
            
                Score: 0,143
             
- 
            Decreased bone turnover in HIV-infected children on antiretroviral therapy. Arch Osteoporos. 2018 Apr 05; 13(1):40.
            
            
                Score: 0,139
             
- 
            Effect of Lopinavir and Nevirapine Concentrations on Viral Outcomes in Protease Inhibitor-experienced HIV-infected Children. Pediatr Infect Dis J. 2016 12; 35(12):e378-e383.
            
            
                Score: 0,127
             
- 
            Contribution of Gag and Protease to HIV-1 Phenotypic Drug Resistance in Pediatric Patients Failing Protease Inhibitor-Based Therapy. Antimicrob Agents Chemother. 2016 Apr; 60(4):2248-56.
            
            
                Score: 0,121
             
- 
            Genetic Changes in HIV-1 Gag-Protease Associated with Protease Inhibitor-Based Therapy Failure in Pediatric Patients. AIDS Res Hum Retroviruses. 2015 Aug; 31(8):776-82.
            
            
                Score: 0,115
             
- 
            Plasma lopinavir concentrations predict virological failure in a cohort of South African children initiating a protease-inhibitor-based regimen. Antivir Ther. 2014; 19(4):399-406.
            
            
                Score: 0,105
             
- 
            Adherence and viral suppression among infants and young children initiating protease inhibitor-based antiretroviral therapy. Pediatr Infect Dis J. 2013 May; 32(5):489-94.
            
            
                Score: 0,099
             
- 
            Switching children previously exposed to nevirapine to nevirapine-based treatment after initial suppression with a protease-inhibitor-based regimen: long-term follow-up of a randomised, open-label trial. Lancet Infect Dis. 2012 Jul; 12(7):521-30.
            
            
                Score: 0,092
             
- 
            Rapid development of antiretroviral drug resistance mutations in HIV-infected children less than two years of age initiating protease inhibitor-based therapy in South Africa. AIDS Res Hum Retroviruses. 2011 Sep; 27(9):945-56.
            
            
                Score: 0,086
             
- 
            Antiretroviral therapy outcomes in HIV-infected children after adjusting protease inhibitor dosing during tuberculosis treatment. PLoS One. 2011 Feb 23; 6(2):e17273.
            
            
                Score: 0,085
             
- 
            Induction therapy with protease-inhibitors modifies the effect of nevirapine resistance on virologic response to nevirapine-based HAART in children. Clin Infect Dis. 2011 Feb 15; 52(4):514-21.
            
            
                Score: 0,085
             
- 
            Initial response to protease-inhibitor-based antiretroviral therapy among children less than 2 years of age in South Africa: effect of cotreatment for tuberculosis. J Infect Dis. 2010 Apr 15; 201(8):1121-31.
            
            
                Score: 0,080